Separate Moderna, Novavax efforts focusing on combined COVID-19/flu vaccine
Two separate efforts are underway to provide the public with a combination vaccine that would deliver simultaneous protections against COVID-19 and influenza. Moderna today announced its effort during a research-and-development presentation, in which a vaccine would be encoded for the COVID-19 spike protein and flu hemagglutinin glycoproteins. Novavax yesterday said its own effort, which is in a phase 1/2 clinical trial, combines within a single formulation its recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates with a patented saponin-based adjuvant.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…